Article
Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways.
Blood - 1 Jan 2015
Gröschel Stefan, Sanders Mathijs A, Hoogenboezem Remco, Zeilemaker Annelieke, Havermans Marije, Erpelinck Claudia, Bindels Eric M J, Beverloo H Berna, Döhner Hartmut, Löwenberg Bob, Döhner Konstanze, Delwel Ruud, Valk Peter J M
Abstract excerpt
Myeloid malignancies bearing chromosomal inv(3)/t(3;3) abnormalities are among the most therapy-resistant leukemias. Deregulated expression of EVI1 is the molecular hallmark of this disease; however, the genome-wide spectrum of cooperating mutations in this disease subset has not been systematically elucidated. Here, we show that 98% of inv(3)/t(3;3) myeloid malignancies harbor mutations in genes activating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.